Anupam Rasayan completes ₹1,750 crore Bliss GVS stake buy
In short
Anupam Rasayan completed a ₹1,750 crore deal to buy 48.2% of Bliss GVS Pharma. The purchase was done through a promoter/share purchase agreement at ₹299 per share, plus an open offer and a small market buy.
This gives the Surat-based company a bigger move into finished medicines. The report does not say how the deal will affect earnings or operations.
What the reporting says
Anupam Rasayan completed a ₹1,750 crore acquisition of a 48.2% stake in Bliss GVS Pharma, according to publisher summaries. The deal was executed through a promoter/SPA route at ₹299 per share, plus an open offer and a small on-market top-up. The immediate consequence is Anupam Rasayan’s expansion into finished pharmaceutical formulations, while any longer-term integration impact is not stated in the available reporting.
Why it matters
Anupam Rasayan completed its ₹1,750 crore purchase of a 48.2% stake in Bliss GVS Pharma, using a promoter/SPA route at ₹299 per share, with an open offer and a small on-market top-up. The publisher summary says this is the company’s third strategic inorganic transaction and expands it into finished pharmaceutical formulations. The deal affects both companies, but post-deal financial impact is not stated.